Overview

IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)

Status:
Terminated
Trial end date:
2021-10-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of PF-06650833 in addition to standard-of-care compared to standard-of-care treatment alone in improving outcomes in patients with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
Pfizer